Search Results - "Bakker, Daphne S"
-
1
Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry
Published in Allergy (Copenhagen) (01-01-2020)“…Introduction Dupilumab has recently been approved for the treatment of moderate to severe atopic dermatitis (AD) in adults. Daily practice data on dupilumab…”
Get full text
Journal Article -
2
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry
Published in British journal of dermatology (1951) (24-08-2023)“…Abstract Background Limited data are available regarding patient-centred dosing of dupilumab for atopic dermatitis (AD) in daily practice. Objectives To…”
Get full text
Journal Article -
3
Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients
Published in Clinical and experimental allergy (01-06-2022)Get full text
Journal Article -
4
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
Published in Acta dermato-venereologica (16-02-2023)“…Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However,…”
Get full text
Journal Article -
5
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
Published in Acta dermato-venereologica (24-11-2022)“…Clinical trials have shown that baricitinib, an oral selective Janus kinase 1/2 inhibitor, is effective for the treatment of moderate-to-severe atopic…”
Get full text
Journal Article -
6
Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
Published in Acta dermato-venereologica (19-10-2021)“…Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of…”
Get full text
Journal Article -
7
Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy
Published in Therapeutic Advances in Chronic Disease (01-09-2018)“…Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. The prevalence of AD is increasing and is currently estimated at 10–20% in…”
Get full text
Book Review Journal Article -
8
Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers
Published in Journal of allergy and clinical immunology (01-01-2021)“…Atopic dermatitis (AD) is a highly heterogeneous disease, both clinically and biologically, whereas patients are still being treated according to a…”
Get full text
Journal Article -
9
Unraveling heterogeneity in pediatric atopic dermatitis: Identification of serum biomarker based patient clusters
Published in Journal of allergy and clinical immunology (01-01-2022)“…Increasing evidence shows that pediatric atopic dermatitis (AD) differs from adult AD on a biologic level. Broad biomarker profiling across a wide range of…”
Get full text
Journal Article -
10
Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis
Published in Journal of investigative dermatology (01-08-2021)“…Dupilumab, a mAb targeting IL-4 receptor alpha (IL-4Rα), markedly improves disease severity in patients with atopic dermatitis. However, the effect of IL-4Rα…”
Get full text
Journal Article -
11
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry
Published in Journal of the American Academy of Dermatology (01-04-2021)“…Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited. To study 52-week effectiveness and safety of…”
Get full text
Journal Article -
12
Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis
Published in JAMA dermatology (Chicago, Ill.) (01-11-2023)“…Since the increased use of dupilumab for atopic dermatitis (AD) in daily practice, several cases have been reported on the development of cutaneous T-cell…”
Get more information
Journal Article -
13
IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval
Published in Clinical and experimental allergy (01-11-2023)Get full text
Journal Article -
14
Biological Tipping Point in Patients with Atopic Dermatitis Treated with Different Dosing Intervals of Dupilumab
Published in Journal of investigative dermatology (01-09-2023)Get full text
Journal Article -
15
Differential dynamics of TARC during JAK‐inhibitor therapy compared to biological therapies targeting type 2 inflammation
Published in Clinical and experimental allergy (01-04-2024)Get full text
Journal Article -
16
-
17
EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers
Published in Allergy (Copenhagen) (01-12-2020)Get full text
Journal Article -
18
Muscle and joint pain during dupilumab treatment for atopic dermatitis: Lack of association with antinuclear antibodies
Published in Clinical and experimental allergy (01-05-2023)Get full text
Journal Article -
19
-
20
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry
Published in Pediatric allergy and immunology (01-12-2022)“…Background Dupilumab has proven to be an effective and safe treatment for atopic dermatitis (AD) in pediatric patients in clinical trials. However, few daily…”
Get full text
Journal Article